Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
Executive Summary
OTC proton pump inhibitors should carry a warning that the products do not eliminate risks of esophageal cancer from persistent heartburn, says the Esophageal Cancer Action Network in a citizen petition to US FDA. FDA should “immediately” require the warning, which should be bold and prominent.
You may also be interested in...
OTC Switch Interest Cooled By Study Costs To Update Safety Data
Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.
OTC Switch Interest Cooled By Study Costs To Update Safety Data
Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.
GSK Consumer Leaving Costa Rica: Consumer Health News Roundup
GSK closing Costa Rica consumer product plant; PPI study authors suggest physicians’ counsel on OTC use; and Makesense topicals recall.